MediGene puts clinical phase I study with RhuDex® on hold(07/09/2008) Volunteers suffered a heart problem after one of the scheduled treatments of RhuDex MediGene AG has put an ongoing phase I study involving the drug candidate RhuDex® on hold. According to information obtained by MediGene, one of the volunteers participating in the study suffered a heart problem some days after one of the scheduled ...
MediGene Extends Protection for its EndoTAG Technology by Another European Patent(04/04/2008) Patent opens up additional potential for the commercialization of the EndoTAG platform-technology MediGene AG announced that the European Patent Office has granted a patent on the EndoTAG® technology which covers certain cationic liposomal compositions containing cytotoxic agents. The patent portfolio hence protects the substance EndoTAG®-1 ...
MediGene Achieves Excellent Efficacy Data of EndoTAG(TM)-1 in Clinical Phase II Trial in Pancreatic Carcinoma(03/19/2008) Novel mode of action of selectively destroying tumor vascularization has been demonstrated MediGene AG achieved excellent efficacy data in a clinical phase II trial of EndoTAG(TM)-1 in the indication pancreatic carcinoma. The trial in 200 patients showed substantially extended survival time of those patients treated with EndoTAG(TM)-1 in ...
MediGene AG: Cancer-Fighting Virus Shows Promise In Early Clinical Trial(07/10/2007) A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said at the ESMO Conference Lugano (ECLU), Switzerland.The virus, called NV1020, ...
MediGene Obtains European Patent on EndoTAG(TM)-1(02/20/2007) MediGene AG announced that the US patent office has granted a patent covering the drug candidate EndoTAG(TM)-1. The patent protects the substance EndoTAG(TM)-1 developed by MediGene as a drug for the treatment of various types of cancer.MediGene has ...
Top
